Aleph Therapeutics, Inc.
- UEI
- PH2KFR4TMT84
- CAGE
- 7PR95
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Targeting covid-19 with a therapeutic interfering particle | National Institute of Allergy and Infectious Diseases (NIH) | $1,195,928 | |
| A vaccine for acute flaccid myelitis | National Institute of Allergy and Infectious Diseases (NIH) | $250,215 |
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Vanderbilt University Medical Center | U19AI181979 | $990,000 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Akanocure Pharmaceuticals Inc. | West Lafayette, IN | — |
| Creative Biotherapeutics LLC | Gurnee, IL | — |
| Invvax, Inc. | Cypress, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Autonomous Therapeutics Inc. | Silver Spring, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Zabbio, Inc. | Del Mar, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Aleph Therapeutics, Inc. is a for-profit corporate entity registered in SAM.gov since July 5, 2016, located in Stanford, California. The company specializes in developing innovative therapeutic technologies, with a primary focus on viral research and potential antiviral treatments. While limited information is available about its comprehensive corporate profile, the organization appears to be concentrated on advanced biotechnology solutions targeting complex viral diseases and developing potentially breakthrough medical interventions.
Through federal grant awards, Aleph Therapeutics, Inc. has been actively engaged in cutting-edge viral research, primarily supported by the National Institute of Allergy and Infectious Diseases (NIAID). The company's grant-funded projects include developing a therapeutic interfering particle (ETIP1) aimed at inhibiting SARS-CoV-2 replication, which demonstrates potential for broad-spectrum antiviral applications across multiple virus types including enteroviruses, respiratory viruses, and influenza. Another notable project focuses on developing a vaccine for acute flaccid myelitis. Additionally, the company has been involved in a sub-grant award with Vanderbilt University Medical Center for the Bunyavirus and Picornavirus Pandemic Pathogen Preparedness (BP4) Center, indicating its participation in collaborative research efforts to address potential pandemic threats. These grant awards, ranging from 2020 to 2024, underscore Aleph Therapeutics' commitment to advancing medical research and developing innovative solutions for viral disease prevention and treatment.
Quick answers
Is Aleph Therapeutics, Inc. registered in SAM.gov?
Aleph Therapeutics, Inc.'s SAM.gov registration expired on August 2, 2026.
What is Aleph Therapeutics, Inc.'s most recent federal award?
Aleph Therapeutics, Inc.'s most recent federal grant award is Targeting covid-19 with a therapeutic interfering particle (R41AI157129), from National Institute of Allergy and Infectious Diseases (NIH), on April 5, 2021.
On GovTribe
See Aleph Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors